PEG-MGF - Pegylated Mechano Growth Factor 2mg

Category:- Hormones | Type:- Injection

Each vial contains: PEG-MGF (Lyophillized) 2mg

Description:
PEG-MGF (Pegylated Mechano Growth Factor) is a Research Peptide Hormone Mechano Growth Factor adds pegylation process to amino acid peptides synthesis is an original interlaced variant of IGF-1 (Insulin Like Growth Factor-I). It is sterile, white lyophilized powder intended for anabolic enhancement, including bony and soft tissue repair (e.g., tendon, ligament, muscle) following injury.

PHARMACOLOGICAL CLASSIFICATION:
PEG-MGF is Pegylated Mechano Growth Factor, long-acting variant of MGF, with significantly extended biological elimination half-life: Main disadvantage of MGF (IGF-1Ec) is an extremely short half-life, calculated in a few minutes only (only 5-7 minutes). Pegylation is the process of joining 1 or more strings with the aid of a substance called polyethylene glycol (PEG) molecule to the protein or peptide.

Pharmacokinetics:
Absorption
Following a subcutaneous injection of single dose of PEG-MGF in healthy male and female adults,the extent of absorption was 292 hr.µg/L and peak concentration was 37µg/L.

Distribution:
The mean volume of distributuion PEG-MGF following administration to healthy adult was estimated to be 14 L/Kg.

Metabolism and elimination:
Metabolism fate of this drug involves classical protein catabolism in both the liver and in kidney.

INDICATIONS:
Primarily, MGF is used in conditions requiring  anabolic enhancement, including bony and soft tissue repair (e.g., tendon, ligament, muscle) following injury, sarcopenia (muscle wasting), stroke, or heart attack.

CONTRAINDICATIONS:
PEG-MGF should not be used when there is any evidence of neoplastic activity. Intracranial lesions must be inactive and antitumor therepy complete prior to the institution of therapy. PEG-MGF should be discontinued if there is evidence of tumor growth.

PREGNANCY AND LACTATION:
Pregnancy category B reproduction studies carried out with PEG MGF. there are, however, no adequate and well controlled studies in pregnant women. Because animal reproduction studies are not always predictive to human response, this drug should be used in pregnancy only if clearly needed.

Breast-feeding
There have been no studies conducted in nursing mothers.

WARNINGS AND PRECAUTIONS:
PEG-MGF should be used with caution in patients who are prone to  hypoglycemia. Furthermore,  patient-specific dosing and injection schedules are vital to avoid unwanted tissue hypertrophy.

DOSAGE AND DIRECTIONS FOR USE;
Bilateral dosing can be used. Single site administration is also effective. PEG MGF has half-life (several days) and does not need to be consecutively administrated. When injected two-three times per week, it keeps concentration for a long period. The cycle duration is five-six weeks. Administration should take place post workout or on recovery days when you plan on resting. Reconstituting: Gently inject 2,5 ml of bacteriostatic water into the vial. Let it sit in refrigerator for 10 - 15 minutes. If there are any undissolved particles left after 15 minutes, gently rotate the vial between your fingers until all of the powder has dissolved and you are left with clear liquid. All our peptides have a purity of at least 98%, most higher than 99%. Peptides are susceptible to heat so our peptides are kept as lyophilised powder in temperature-controlled medical fridges until the time of packaging. Shipments are hand-delivered to the post office at specific times in order to avoid exposure to heat for long periods of time while in the care of postal services. This ensures that the peptide you receive is as pure as possible.

ATTENTION: This compound should be used for research purposes only. All chemical compounds have risks. Please consult your physician and understand the available research before consumption. This product is not intended to diagnose, treat, cure, or prevent any disease.

SIDE EFFECTS:
Short term local injection site reactions includes, suchas pain, numbness, redness and swelling. The subcutaneous administration of growth hormone at the same injection site over a long period may result in local lipoatrophy. Disturbance in fluid balance ( swelling,), joint pain, muscle pain, stiffness of hands and feets, numbness. these adverse reactions are common in adukts but are uncommon in children.

DRUG INTERACTIONS:
Concomitant glucocorticoid treatment may inhibit the growth promoting effect of of PEG MGF. Pediatric patients with coexisting ACTH deficiency should have their glucocorticoid replacement dose carefully adjusted to avoid an inhibitory effect on growth.

STORAGE INSTRUCTIONS:
Lyophilised peptide must be stored at -20°C and peptide solution at 4°C. Before mixing, keep between -18 and -20°C. Use within 24 months. Once reconstituted use within 20 days. Do not freeze once reconstituted.